Delphine Kerob, MD, is the La Roche-Posay International Scientific Director and a dermatologist for Saint Louis hospital in Paris.

How Are Career and Education Opportunities Impacted by Atopic Dermatitis? 

A new international analysis published in the 

 is highlighting the long-term consequences of 

 beyond its physical symptoms, suggesting the disease may shape educational, professional, and social outcomes long after skin lesions have resolved.

Childhood-onset atopic dermatitis may leave lasting “invisible scars”:

 Kerob emphasized that even when atopic dermatitis resolves, the disease can have lifelong effects.

The impact of AD extends far beyond the skin:

 Factors such as chronic itch, sleep disruption, anxiety, attention difficulties, stigmatization, and bullying may contribute to the greater educational and professional challenges.

Clinicians should take a more holistic approach to pediatric atopic dermatitis care:

 Kerob said dermatologists should assess not only disease severity but also sleep quality, mental health, school experiences, and other psychosocial factors.

, Delphine Kerob, MD, dermatologist at Saint Louis Hospital in Paris and Scientific Director at La Roche-Posay Laboratoire Dermatologique, discussed the findings and their implications for clinicians caring for children with atopic dermatitis, a common form of eczema.

The multinational cross-sectional study analyzed data from more than 22,000 individuals across 27 countries and found that patients with childhood-onset atopic dermatitis reported significantly greater limitations in educational and career choices than those whose disease began later in life. Among childhood-onset patients, more than one-third reported restricted study choices and career limitations, while many also described adapting their living or working environments because of their disease. The study additionally identified higher rates of social avoidance and persistent workplace challenges, even among individuals whose disease had resolved.

For Kerob, the findings reinforce the idea that atopic dermatitis can leave lasting “invisible scars” despite the absence of permanent physical scarring.

“I think that what the big [lesson] of this study is is that even though atopic dermatitis doesn't lead to visible scars, it can leave an invisible print,” Kerob said. She noted that the burden linked with childhood atopic dermatitis may persist throughout a patient’s life, regardless of whether the disease eventually resolves.

According to Kerob, the study underscores the need for clinicians to evaluate atopic dermatitis more broadly than as a skin disease alone. She pointed to several factors that may contribute to the long-term impact observed among patients, including sleep disruption from chronic itch, difficulties with concentration, anxiety, attention disorders, and social stigmatization associated with visible skin lesions. Children may also face bullying or exclusion at school, experiences that can compound the disease burden and influence future life trajectories.

Kerob suggested that these overlapping challenges may help explain why patients with childhood-onset disease reported greater educational and occupational limitations later in life. Beyond the visible manifestations of atopic dermatitis, she emphasized the uncertainty associated with a chronic relapsing condition, noting that patients often do not know when flares will occur or whether their disease will ultimately resolve. Persistent symptoms, ongoing treatment needs, and undertreated inflammation may all contribute to feelings of being different from peers without atopic dermatitis.

Ultimately, Kerob said the findings should encourage dermatologists to take a more comprehensive approach to pediatric disease management. While many children will see their disease improve with age, she argued that clinicians should proactively assess psychosocial burden, school experiences, sleep quality, and comorbid conditions alongside traditional measures of disease severity. By recognizing these broader impacts early, providers may be better positioned to reduce the lifelong consequences associated with atopic dermatitis.

Disclosures: Delphine Kerob is a full-time employee of La Roche Posay Laboratoire Dermatologique and has been employed by Laboratoires Vichy, France, and L’Oreal.

Scars of life: study shows impact of atopic dermatitis on educational and career choices. EurekAlert! May 28, 2026. Accessed June 2, 2026. 

https://www.eurekalert.org/news-releases/1129244?

Stratigos A, Steinhoff M, Luger T, et al. Impact of atopic dermatitis on education and career choices: the Scars of Life international study. Journal of Investigative Dermatology. May 28, 2026. Accessed June 2, 2026. 

https://www.jidonline.org/article/S0022-202X(26)01041-9/fulltext

Videos

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 has issued a complete response letter (CRL) for CTx-1301 (dexmethylphenidate HCl), declining to approve the investigational once-daily 

 treatment at this time, according to an announcement from Cingulate on June 2, 2026.

The FDA issued a CRL for CTx-1301 (dexmethylphenidate HCl), a once-daily ADHD treatment, citing Chemistry, Manufacturing, and Controls (CMC) information requests

No concerns were raised regarding clinical safety or efficacy

Two pivotal phase 3 studies—one in adults, one in children and adolescents—demonstrated meaningful improvements on validated ADHD symptom scales

CTx-1301 uses a multi-core tablet design to deliver three timed drug releases over 12–16 hours

Cingulate says CMC work is already underway and resubmission is the immediate priority

FDA Cites CMC Requests, Raises No Clinical Concerns

The FDA's letter cited requests for additional Chemistry, Manufacturing, and Controls (CMC) information. The agency did not identify any concerns related to the clinical safety or efficacy of CTx-1301.

“We are encouraged that the FDA’s response was limited to specific information requests related to CMC and did not currently identify any issues related to the clinical safety or efficacy of CTx-1301,” said Cingulate CEO Shane J. Schaffer.

The decision follows an FDA review of 2 pivotal phase 3 studies demonstrating clinically meaningful improvements in validated ADHD symptom scales across both pediatric and adult populations, with a tolerability profile consistent with the broader methylphenidate class and no serious treatment-emergent adverse events reported in either trial.

Phase 3 Data Supported Efficacy Across Age Groups

The adult dose-optimization trial (CTx-1301-022) was a single-center, double-blind, randomized, placebo-controlled, parallel-group study in 21 adults aged 18 to 55 years with ADHD.

 Following 5-week dose-optimization phase titrating participants to between 25 mg and 50 mg, participants were randomized to CTx-1301 or placebo. The primary endpoint (the Permanent Product Measure of Performance (PERMP)_ was met, with effect sizes ranging from 0.88 to 2.60 across the active-day assessment window. The Adult ADHD Investigator Symptom Rating Scale (AISRS) and Clinical Global Impression–Severity (CGI-S) also favored active treatment.

The pediatric fixed-dose study (CTx-1301-005) was a randomized, double-blind, placebo-controlled trial in children and adolescents aged 6 to 17 years.

 CTx-1301 produced dose-dependent improvements on the ADHD Rating Scale 5 (ADHD-RS-5), CGI-Improvement (CGI-I), and CGI-S, with the 37.5 mg dose producing the largest observed effect size. Safety findings were consistent with the methylphenidate class, and no unexpected adverse events were reported.

CTx-1301 is a once-daily, multi-core tablet that delivers 3 precisely timed releases of active drug over the course of a single dose. Data supports its onset within the first hour post-dose and sustained efficacy through approximately 12 to 16 hours. CTx-1301’s active ingredient—dexmethylphenidate, the pharmacologically active d-threo-enantiomer of methylphenidate—has been FDA-approved in immediate- and extended-release forms since 2001 and 2005, respectively.

ADHD affects an estimated 20 million people in the US, including 8 million children and 12 million adults.

Stimulants remain the gold-standard pharmacologic treatment, supported by decades of data and endorsed by major clinical guidelines, including those from the American Academy of Pediatrics. However, current extended-release formulations may not provide symptom control through late afternoon and evening, often requiring booster doses that add dosing complexity and may disrupt sleep.

Dexmethylphenidate exerts its therapeutic effect primarily by blocking dopamine and norepinephrine transporters in prefrontal cortical and subcortical circuits involved in attention regulation and impulse control.

 As the more pharmacologically active enantiomer of methylphenidate, it provides symptom relief at lower absolute doses than racemic formulations.

“Our immediate priority is to complete the CMC work already underway with our manufacturing partner,” Schaffer continued. “We believe the outstanding requests will be addressed quickly as we move efficiently toward resubmission.”

Cingulate Receives Complete Response Letter from FDA for CTx-1301 - Cingulate Inc. Cingulate Inc. Published 2026. Accessed June 2, 2026. 

https://www.cingulate.com/news-releases/news-release-details/cingulate-receives-complete-response-letter-fda-ctx-1301 

Cingulate Inc. FDA accepts Cingulate's new drug application for CTx-1301 in attention-deficit/hyperactivity disorder (ADHD) and sets a May 31, 2026 PDUFA date. News release. October 14, 2025. 

https://www.globenewswire.com/news-release/2025/10/14/3166151/0/en/fda-accepts-cingulate-s-new-drug-application-for-ctx-1301-in-attention-deficit-hyperactivity-disorder-adhd-and-sets-a-may-31-2026-pdufa-date.html

Cingulate Inc. Cingulate presents positive phase 3 results for CTx-1301 demonstrating statistically significant efficacy and entire active-day symptom control. News release. October 28, 2025. 

https://www.globenewswire.com/news-release/2025/10/28/3172555/0/en/Cingulate-Presents-Positive-Phase-3-Results-for-CTx-1301-Demonstrating-Statistically-Significant-Efficacy-and-Entire-Active-Day-Symptom-Control.html

ClinicalTrials.gov. Phase 3 efficacy and safety study in adults with ADHD using CTx-1301 (CTx-1301-022). NCT05631626. 

https://clinicaltrials.gov/study/NCT05631626

Kang J. Novel Dexmethylphenidate Formulation Improves Pediatric ADHD Symptoms. MPR. Published May 20, 2025. Accessed May 29, 2026. 

https://www.empr.com/news/novel-dexmethylphenidate-formulation-improves-pediatric-adhd-symptoms/

Liu F, Minami H, Silva RR. Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. 

. 2006;2(4):467-473. doi:10.2147/nedt.2006.2.4.467

McGough JJ, Pataki CS, Suddath R. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. 

. 2005;5(4):437-441. doi:10.1586/14737175.5.4.437

Wolraich ML, Hagan JF Jr, Allan C, et al; Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. 

Dexmethylphenidate - an overview | ScienceDirect Topics. www.sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/dexmethylphenidate

Articles

The FDA issued a complete response letter for CTx-1301, a once-daily dexmethylphenidate formulation for ADHD, citing the need for additional Chemistry, Manufacturing, and Controls information. No clinical safety or efficacy concerns were raised. Two phase 3 studies in adults and pediatric patients showed statistically significant, clinically meaningful improvements across validated symptom and performance measures, with tolerability consistent with the methylphenidate class and no serious treatment-emergent adverse events. The multi-core tablet provides three timed releases supporting rapid onset and 12–16-hour coverage.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.

FDA News

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns

Jonathan A. Bernstein, MD: University of Cincinnati

BTK Inhibitors, C-Kit Agents, and Remission in CSU: What the Pipeline Suggests

Can Patients with CSU Achieve True Remission?

is a realistic goal, but the field lacks the longitudinal data and validated biomarkers to reliably identify which patients will get there, according to Jonathan Bernstein, MD, professor of medicine at the University of Cincinnati and physician with Bernstein Allergy Group and the Bernstein Clinical Research Center.

Bernstein presented on endotyping and biomarker strategies in CSU at the 

 about where the pipeline stands and what clinicians can apply now.

Read parts 1 and 2 of the interview with Bernstein here: 

Endotyping & Biomarkers in CSU, With Jonathan Bernstein, MD

Sequencing Emerging Therapies in CSU, With Jonathan Bernstein, MD

Remibrutinib (BTK inhibitor) and c-kit inhibitors are among agents with theoretical potential for CSU remission; dupilumab and omalizumab are not expected to accelerate it

The CU index is not yet validated; basophil-based assays may not accurately reflect mast cell activity

Distinguishing spontaneous from drug-induced remission requires longitudinal study designs not yet available

Available biomarkers can support shared decision-making and expectation-setting even without full clinical validation

Which Agents Have the Best Shot at Inducing Remission?

Among emerging therapies, Bernstein cited remibrutinib, a BTK inhibitor positioned further downstream in the disease pathway, as a candidate with plausible mechanistic grounds for inducing remission. C-kit inhibitors were also flagged as potentially meaningful given their action on mast cells, the primary effector cells in CSU. By contrast, Bernstein said he would not expect dupilumab or omalizumab to accelerate remission.

"We don't have that information yet," he noted, adding that well-designed studies examining time course and patient-level predictors of remission are still absent from the literature.

Complicating the picture further: distinguishing drug-induced remission from spontaneous remission remains an unresolved methodological challenge. The World Allergy Organization Urticaria Committee has proposed defining CSU clinical remission as total resolution of urticaria signs and symptoms without pharmacotherapy for ≥ 6 months, though the implications of this definition in clinical practice must still be evaluated and validated in future studies.

Current data show no significant difference in CSU relapse between 6- and 12-month periods of remission.

Biomarker Implementation: Where the Gaps Are

On the barriers to routine biomarker use, Bernstein pointed to 3 core problems: lack of validation, unclear cut points, and uncertain predictive value across treatment responders and non-responders.

He highlighted the CU index as a specific example, which is not yet validated and primarily reflective of basophil activity rather than mast cell behavior. Because mast cells are tissue-based and represent a distinct lineage from basophils, translating basophil-derived assay data to clinical decision-making has limits.

Composite immunological signatures integrating multiple biomarkers hold promise for guiding therapeutic decisions, and implementing validated markers could enable earlier identification of difficult-to-treat patients and more targeted therapy.

 But that infrastructure is not yet in place.

Bernstein's message to clinicians leaving EAC: patients with CSU are diverse, and better phenotyping, even with imperfect tools, supports more productive patient conversations.

"Do we have the right biomarkers yet? Not necessarily," Bernstein said. "Do the ones we have add to the conversation with our patients? They certainly do. That’s where I think clinicians should take advantage of this, and I think it might also be more gratifying when you're treating patients to know that you can really give them some additional guidance in terms of treatment expectations and outcomes.”

Editor’s note: SANOFI-AVENTIS U.S., Pharming Healthcare, Novartis Pharmaceuticals Corporation, BioCryst Pharmaceuticals, Regeneron Healthcare Solutions, CSL Behring, Blueprint Medicines Corporation, Dermavant Sciences, Incyte Corporation, Eli Lilly and Company, and more.

Sánchez J, Pite H, Gómez RM, et al. Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper. J Allergy Clin Immunol. 2025;155:1050–1056. 

https://www.jacionline.org/article/S0091-6749(24)02413-8/abstract

Calzari P, Favale EM, Cugno M, et al. Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria. Front Allergy. 2026. doi:10.3389/falgy.2025.1728559. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12832613/

 Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

BTK Inhibitors, C-Kit Agents, and Remission in CSU: What the Pipeline Suggests  

Jamie Wood, MD, is the medical director of pediatric diabetes at UH Rainbow Babies and Children’s Hospital.

Afrezza’s Pediatric Approval and Improving Adolescent Diabetes Care

On May 29, 2026, the US Food and Drug Administration (FDA) announced its approval of Afrezza, MannKind’s inhaled insulin, for adolescent patients aged 6 years and older with type 1 diabetes (T1D) or type 2 diabetes (T2D).

Optimal glycemic control among pediatric patients with diabetes is a consistent challenge, with many often missing or delaying meal or snack boluses. Additionally, >350,000 children and adolescents in the US currently live with diabetes, many of whom rely on lifelong insulin therapy. To discuss the impact this approval may have on the field of pediatric diabetes care, the editorial team at 

 spoke with Jamie Wood, MD, medical director of pediatric diabetes at UH Rainbow Babies and Children’s Hospital, and an investigator in the pivotal INHALE-1 trial of Afrezza in pediatric patients.

“Youth with type 1 and type 2 diabetes still have a lot of unmet needs in their management, despite all of the advances that have already happened,” Wood told 

“A lot of these unmet needs are around psychosocial issues like distress and diabetes burden, as well as the challenges of daily management. Inhaled insulin, otherwise known as Afrezza, can help with a few of those barriers.”

Conducted across 38 endocrinology practices in the US for 26 weeks, INHALE-1 enrolled patients between the ages of 4 and 17 years. Other eligibility criteria included a clinical diagnosis of T1D for ≥6 months or T2D for ≥3 months treated with multiple daily injections (MDIs) of insulin for ≥2 weeks, as well as an HbA1c of 7-11%. Patients were excluded if they had received asthma treatment in the prior 12 months or had experienced diabetic ketoacidosis (DKA) or severe hypoglycemia in the prior 90 days, among other criteria.

Patients were randomly assigned in a 1:1 ratio to receive either inhaled insulin or rapid-acting analog (RAA) insulin, plus continuation of long-acting basal insulin and continuous glucose monitoring (CGM) for 26 weeks. Additionally, investigators monitored binary HbA1c metrics and CGM metrics. Safety outcomes included severe hypoglycemia, DKA, and all adverse events.

A total of 313 patients were initially screened for inclusion – of these, 230 were enrolled to either the inhaled insulin arm (n = 117) or the RAA arm (n = 113). Mean age across both groups (+/- standard deviation [SD]) was 12.6 +/- 3 years and mean HbA1c was 8.2% +/- 0.9%. T1D was present in 225 patients (98%) and T2D was present in 5 patients (2%).

Ultimately, patients in the inhaled insulin arm displayed a mean HbA1c of 8.41 +/- 1.38 at 26 weeks, while those in the RAA arm had a mean HbA1c of 8.21 +/- 1.1 (adjusted difference = 0.18; 95% CI, -0.08 to 0.43; noninferiority 

 = .091). CGM-measured time in range was not substantially different between groups. The inhaled insulin group did, however, report greater treatment satisfaction and displayed less gain in weight than the RAA group.

Despite failing to meet the prespecified criteria for HbA1c noninferiority, the trial did demonstrate inhaled insulin’s safety and associated it with greater treatment satisfaction and less weight gain compared with RAA. When taken in conjunction with additional safety data collected over 20 years of investigating Afrezza in adult and pediatric patients, these data were enough for the FDA to justify the approval.

“Just because a trial ends does not mean the monitoring stops,” Wood said. “With FDA approval, we are still going to need to monitor and continue to evaluate for safety and efficacy in kids and adults. Ongoing monitoring is going to be the first priority.”

Editors’ Note: Wood reports no relevant disclosures.

MannKind. MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes. May 29, 2026. Accessed June 1, 2026. 

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-fda-approval-afrezzar-first-and-only-inhaled

Haller MJ, Kanapka L, Monzavi R, et al. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes. Diabetes Care. 2026;49(1):179-187. 

Jamie Wood, MD, discusses the impact of Afrezza’s recent FDA approval for pediatric patients with type 1 and type 2 diabetes.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Christopher G. Bunick, MD, PhD, is an associate professor of dermatology at Yale University School of Medicine.

What Is Next for OX40 Ligand Inhibition in Atopic Dermatitis?

 explored the future potential of amlitelimab in atopic dermatitis, with hosts Christopher Bunick, MD, PhD, and Lindsay Ackerman, MD, emphasizing the importance of maintaining scientific curiosity and clinical perspective as more data emerge regarding OX40 ligand-targeted therapy.

The discussion centered on balancing enthusiasm for a novel therapeutic mechanism with the need for continued investigation into safety signals and patient selection. Bunick argued the field should remain optimistic about amlitelimab’s future, noting that a better understanding of patient-specific risk factors could ultimately help clinicians identify individuals most appropriate for treatment. He compared this approach to the risk stratification strategies dermatologists have already adopted for JAK inhibitors, where clinicians routinely evaluate patients for factors that may increase the likelihood of adverse events before initiating therapy.

Rather than viewing emerging questions about the therapy as a reason to abandon the pathway, Bunick suggested that dermatology should focus on generating more data and demanding greater scientific transparency. In his view, understanding the underlying biology behind observed safety findings will allow clinicians to make more informed, patient-centered decisions while preserving access to potentially valuable treatment options.

Ackerman agreed, describing the OX40-OX40 ligand pathway as an example of why dermatology remains one of the most rapidly evolving areas of medicine. She highlighted the complexity of inflammatory disease biology and suggested that upstream immune modulation may ultimately have implications extending beyond atopic dermatitis. According to Ackerman, the pathway’s broad immunologic relevance could make it important not only for eczema but also for other chronic inflammatory disorders that continue to present therapeutic challenges.

The hosts also discussed the ongoing unmet need in atopic dermatitis despite an expanding therapeutic landscape. Ackerman noted that the disease remains highly heterogeneous, with significant variability in clinical presentation and treatment response. As a result, she argued that continued investment in new mechanisms of action remains essential, even as effective therapies already exist. She pointed to the continued development of amlitelimab as evidence of an ongoing commitment to addressing gaps in care for patients whose disease remains difficult to control.

The conversation then shifted to Ackerman’s firsthand experience as a clinical trial investigator. Drawing on her participation in amlitelimab studies, Ackerman described seeing several patients achieve substantial improvements despite having previously failed multiple therapies. Although she acknowledged that these observations represent only a small number of patients, she noted that some individuals continued to do well even after completing the interventional portion of the study. Ackerman said she had anticipated needing to rapidly transition certain participants to additional treatments after trial completion because of the severity and recalcitrance of their disease, but some had yet to experience significant flares.

Bunick cautioned against drawing broad conclusions from individual cases but viewed those experiences as further reason to remain open-minded. Both hosts ultimately stressed that advancing patient care requires careful scientific investigation, patience, and a willingness to evaluate new therapeutic pathways on the basis of evolving evidence. They concluded that maintaining a patient-centered approach while pursuing deeper mechanistic understanding will be critical as the role of OX40 ligand inhibition continues to develop within atopic dermatitis and potentially other inflammatory diseases.

Editor’s note: This segment was summarized with the help of AI tools.

Relevant disclosures for Bunick include AbbVie, South Beach Symposium, Almirall, Apogee Therapeutics, Arcutis Biotherapeutics, Daiichi Sankyo, Eli Lilly, LEO Pharma, US, Novan, Novartis, Ortho Dermatologics, Palvella Therapeutics, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Timber Pharmaceuticals, and UCB. Relevant disclosures for Ackerman include AbbVie, Alumis, Amgen, Arcutis, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Galderma, L'Oréal, Novartis, Sun Pharmaceutical, and UCB.

Sanofi. Press Release: AAD: new results from Sanofi’s amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session. Sanofi.com. Published March 28, 2026. Accessed June 1, 2026. 

https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-28-15-00-00-3264184

Kyowa Kirin. Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials - Kyowa Kirin. Kyowakirin.com. Published March 3, 2026. Accessed June 1, 2026. 

https://www.kyowakirin.com/media_center/news_releases/2026/e20260303_01.html

The latest ABCs of Dermatology explored the future potential of amlitelimab in atopic dermatitis and the potential of OX40 ligand-targeted therapy.

George Vasquez-Rios, MD, MSCR, FASN, is a nephrologist and glomerular disease specialist and director of the Glomerular & Genetic Diseases Center.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Strategic Alliance Partnership

How Sparsentan is Reshaping Care for Patients With FSGS, With George Vasquez Rios, MD

Marcus Shaker, MD, a professor of pediatrics and medicine at the Dartmouth Geisel School of Medicine

Screenshot 2025-11-06 at 10.12.42 AM.png

Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.

Food Allergy

Early Allergen Introduction in Infants: Reducing Food Allergy Risk Without Routine Testing

Miriam Chung, MD, is an assistant professor of medicine at the Icahn School of Medicine at Mount Sinai

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

Interpreting Sparsentan’s Proteinuria Benefits Despite Missed eGFR Outcomes

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Beyond Step-Up Therapy: Biologic Initiation, Selection, and Access in Asthma and COPD

 Bernstein discussed treatment sequencing, biomarker use, and evolving chronic spontaneous urticaria management strategies during an interview at EAC 2026.


Dr. Kiera Booth, MD, is a board-certified dermatologist practicing at Premier Dermatology & Cosmetic Surgery in the Newark and Middletown, Deleware areas.

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Discussing Raising HS Awareness and Treatments, With Kiera Booth, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Mavacamten sNDA Gets FDA Priority Review for Adolescent Obstructive HCM

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.


Latest News

How Are Career and Education Opportunities Impacted by Atopic Dermatitis?

FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns

BTK Inhibitors, C-Kit Agents, and Remission in CSU: What the Pipeline Suggests

Afrezza’s Pediatric Approval and Improving Adolescent Diabetes Care

What Is Next for OX40 Ligand Inhibition in Atopic Dermatitis?